On March 25, 2026, Imunon, Inc. (IMNN) announced updated overall survival (OS) data from the OVATION 2 trial that showed a now 14.7-month increase in OS (45.1 vs. 30.4 months) for women receiving IMNN-001 along with standard of care (SoC) chemotherapy compared to SoC alone. In addition, women treated with IMNN-001 and SoC along with poly ADP-ribose polymerase (PARP) inhibitors achieved a median increase in OS of 24.2 months (65.6 vs. 41.4 months) compared to SoC alone. The continued increase in OS shows that IMNN-001 is having a meaningful impact in the treatment of ovarian cancer patients, which is particularly important given that there have been no meaningful advances in SoC for ovarian cancer in the past 30 years. Imunon is continuing to enroll patients in the Phase 3 OVATION 3 trial and is expecting to have the trial approximately 20% enrolled within the next year.
